Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study
Xinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu · 2026
Read Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study by Xinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13175792.txt.
Description
Xinfeng Yao and co-authors compare two common diabetes drug classes in real-world care in this 2026 study. Type 2 diabetes keeps growing worldwide, and drug choice shapes long-term health. The two classes work differently: one sheds sugar in urine, the other boosts insulin control.
The retrospective study reviews patients treated over about a year. It compares how well each class lowered blood sugar and how safe each proved. It also hunts for traits that predict a strong response to either class. Real-world records catch effects that tight trials can miss. Doctors choosing a first add-on drug can use the head-to-head picture. Patients gain when that choice starts from evidence.
Catalog record
| CREATOR | Xinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |